Aarti Drugs growth over the years

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Compounded a year	1 yr	3 yr
Revenue	+7.5%	−1.9%
EBITDA	+7.7%	+0.4%
Net Income	+16.0%	+5.4%
EPS (adj.)	+15.9%	+5.4%
Total Assets	+9.4%	+5.2%
Total Equity	+13.1%	+9.1%
Free Cash Flow	+19.0%	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AARTIDRUGS₹449.00

Aarti Drugs Ltd.

· Pharma & Health

₹ CrorePeersALIVUS AARTIPHARM ADVENZYMES AGARWALEYE AKUMS APLLTD CORONA HCGMcap ₹4,098 Cr

Annuals · FY-end closes

Compounded Growth Annuals · CAGR %	1Y CAGR	3Y CAGR
Revenue	+7.5	-1.9
EBITDA	+7.7	+0.4
Net Income	+16.0	+5.4
EPS (adj.)	+15.9	+5.4
Total Assets	+9.4	+5.2
Total Equity	+13.1	+9.1
Free Cash Flow	+19.0	—

CAGR from filed annuals — needs positive start & end values.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.